Patients with a higher expression level of CXXC1 had a worse prognosis for liver hepatocellular carcinoma (LIHC) but a better prognosis for bladder urothelial carcinoma (BLCA) and uterine corpus endometrial carcinoma (UCEC). This evidence concerns the gene CXXC1 and bladder transitional cell carcinoma.